Entries |
Document | Title | Date |
20080293809 | Pest control formulation - The present invention relates to a pest control composition that includes a pest control active ingredient and a polyoxypropylene-polyoxyethylene ether of a long chain fatty alcohol as an agent to reduce or eliminate paraesthesia of the active ingredient to a warm blooded mammal. The system releases the active ingredient efficiently and uniformly. The pest control formulation is less irritating to the animal's skin as compared to prior art systems. The formulation is useful for making animal collars, ear tags, pest strips, liquid spot-on treatments, and the like. | 11-27-2008 |
20100022640 | ESTERS OF 2-PHENYLALKANENITRILES AND ANTIFUNGAL COMPOSITIONS CONTAINING THEM - Esters of 2-phenylalkanenitriles, such as 3-acetoxy-2-(2-chloro-5-(difluoromethoxy)phenyl)propanenitrile and 3-acetoxy-2-(4-chlorophenyl)propanenitrile, and compositions containing such esters, are useful as fungicides at very low concentrations. | 01-28-2010 |
20100035985 | Ester Compound and Use Thereof - An ester compound represented by the formula (1): | 02-11-2010 |
20100081714 | INSECTICIDAL MIXTURE CONTAINING GAMMA-CYHALOTHRIN - Mixtures containing gamma-cyhalothrin [(S)-α-cyano-3-phenoxybenzyl (Z)-(1R,3R)-3-(2-chloro-3,3,3-trifluoro-1-propenyl)-2,2-dimethylcyclopropanecarboxylate] and another compound having insecticidal, nematicidal, acaricidal, molluscicidal, fungicidal, plant growth regulating or herbicidal activity are provided. Compositions containing the mixture and insecticidal methods using such mixtures or compositions are also provided. | 04-01-2010 |
20100130602 | PESTICIDAL COMPOSITION AND METHOD FOR CONTROLLING HARMFUL INSECTS - A pesticidal composition containing: 4-methoxymethyl-2,3,5,6-tetrafluorobenzyl 3-(2-cyano-1-propenyl)-2,2-dimethylcyclopropanecarboxylate, a saturated hydrocarbon having an initial boiling point of 150° C. or higher and a 95%-distillation temperature of 300° C. or lower, and at least one alkyl carboxylate ester selected from the group consisting of the following esters (i) to (iii): (i) alkyl alkylcarboxylate esters having 12 to 20 carbon atoms, (ii) dialkyl dicarboxylate esters having 12 to 20 carbon atoms, and (iii) trialkyl acetylcitrate esters having 12 to 20 carbon atoms; has an excellent pesticidal acivity. | 05-27-2010 |
20100210719 | O-DESMETHYLVENLAFAXINE - Processes for preparing desvenlafaxine and stable amorphous O-desmethylvenlafaxine succinate solid dispersions with one or more pharmaceutically acceptable carriers. | 08-19-2010 |
20100234457 | Aqueous microemulsions containing organic insecticide compounds - The present invention relates to new aqueous microemulsions containing one or more organic insecticide compounds and to their use for plant protection, including seed and crop protection, and protection of non-living material. The formulation according to the invention comprises:
| 09-16-2010 |
20100240748 | TETRAHYDRONAPHTHALEN-2-OL DERIVATIVES - The present invention relates to novel tetrahydronaphthalen-2-ol derivatives, to pharmaceutical compositions comprising these compounds and to their use in therapy, in particular to their use for the manufacture of a medicament for the prevention or treatment of lower urinary tract symptoms, benign prostate hyperplasia, prostate cancer, hot flushes, anxiety, depression, breast cancer, medullary thyroid carcinoma, ovarian cancer, inflammatory bowel disease, arthritis, endometriosis, and colon cancer. | 09-23-2010 |
20110046219 | (HET)ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES - Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 2-(3-hydroxy-3-methyl-butyl)-6-(het)aryl-p-quinone or as 2-(3-hydroxy-3-methylbutyl)-3-(het)aryl-p-quinone derivatives. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed. | 02-24-2011 |
20120101156 | COMPOSITIONS COMPRISING A RETINOID AND AN NFkB-INHIBITOR AND THEIR METHODS OF USE - A composition including a retinoid, an NFκB-inhibitor, and a cosmetically-acceptable topical carrier is provided. Methods of treating the skin are also provided. | 04-26-2012 |
20130165512 | COMPOSITIONS COMPRISING A RETINOID AND AN NFkB-INHIBITOR AND THEIR METHODS OF USE - A composition including a retinoid, an NFκB-inhibitor, and a cosmetically-acceptable topical carrier is provided. Methods of treating the skin are also provided. | 06-27-2013 |
20130324601 | PHARMACEUTICAL COMPOSITION FOR TREATING INFLAMMATION AND PAIN - The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a ω-(arylsulfonyl)alkylnitrile compound, or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering an ω-(arylsulfonyl)alkylnitrile compound or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof. | 12-05-2013 |
20150087701 | PHARMACEUTICAL COMPOSITION COMPRISING OMEGA-(ARYLSULFONYL)ALKYLNITRILE - The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a ω-(arylsulfonyl)alkylnitrile compound, or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering an ω-(arylsulfonyl)alkylnitrile compound or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof. | 03-26-2015 |
20150133545 | PYRETHROIDS FOR TREATMENT OF OCULAR MOVEMENT DISORDERS - The present invention relates to the use of a pharmaceutical composition comprising a pyrethroid compound for inhibiting unwanted eye movement and for treating eye movement disorders, such as, but not limited to, nystagmus. The invention is directed to methods for treating unwanted eye movement and eye movement disorders by administering a pharmaceutical composition comprising a pyrethroid compound that is lambda cyhalothrin or an analog thereof, through topical administration of the composition or incorporation of the composition into a contact lens or an ocular device for implantation into the eye. It further provides for pharmaceutical compositions for the treatment of eye movement disorders and methods of preparing them. | 05-14-2015 |
20150297551 | (HET)ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES - Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 2-(3-hydroxy-3-methyl-butyl)-6-(het)aryl-p-quinone or as 2-(3-hydroxy-3-methylbutyl)-3-(het)aryl-p-quinone derivatives. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed. | 10-22-2015 |
20150366824 | INDUCTION OF ESTROGEN RECEPTOR BETA BY CHOLESTEROL BIOSYNTHESIS INHIBITORS AND METHODS OF TREATMENT OF CANCER - Disclosed herein are methods and compositions related to the discovery that cholesterol inhibitors induce the anti-proliferative protein, estrogen receptor beta (ERβ), in both ERα-positive and ERα-negative breast cancer cell lines, including triple negative cells. | 12-24-2015 |
20150366834 | Opsin-Binding Ligands, Compositions and Methods of Use - Compounds are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed. | 12-24-2015 |
20160200675 | 3, 4-BIS-BENZYLSULFONYLBUTYRONITRILE AND ITS PHARMACEUTICAL USE | 07-14-2016 |